COVID-19 Trial Activated in Under a Week Through New Research Program

Cohen Veterans Bioscience is supporting the National Association of Veterans Research Education Foundation (NAVREF) and the new VA Office of Research and Development (ORD) led Partnered Research Program (PRP).

As an outcome of the Access to Clinical Trials (ACT) for Veterans initiative, the PRP increases veterans’ access to high-quality clinical trials to give Veterans access to world-class health solutions. CVB is lending support to NAVREF to help it expand its infrastructure, including the employment of clinical trial facilitators who will help expedite study start-up at VA trial sites.

The launch of the PRP has led to significant reforms in the VA clinical trial process. The most important of these reforms, allowing clinical trial sponsors to use commercial institutional review boards (IRBs), was finalized in March. As a result, when the COVID-19 pandemic hit, the VA was ready to help lead the clinical research response. Since its launch, the VA has launched trial sites in days, not months, including a partnership with the National Institute of Allergy and Infectious Diseases (NIAID) on its COVID-19 trial.

Share this article:

More from CVB

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

New meta-analysis builds upon PTSD genetics research, providing a foundation for the development of precision therapies

Driving Progress: TBI Action Alliance Launches Multi-Pronged Initiative to Speed Development of Diagnostic and Therapeutic Solutions for Traumatic Brain Injury

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.